The finding, reported in the Journal of the National Cancer Institute, draws on data from studies that have tracked the health of tens of thousands of people over several decades.
It suggests that colorectal cancer patients could one day have their tumor tissue tested for the molecular sign, and, if necessary, receive more powerful therapies and a familial cancer-risk assessment for their relatives. It further suggests that such patients' relatives could be eligible for more frequent colonoscopies to catch the disease at the earliest possible stage.
Unlike other abnormalities that raise the risk of colon cancer in some families, the newly discovered sign is not linked to a gene mutation that can be inherited from one's parents or grandparents. It appears in DNA segments that are thought to have entered the human genome millennia ago, possibly through infection by retroviruses. These sections, known as long interspersed nucleotide element 1 (LINE-1), are sprinkled throughout the human genome and make up about 17 percent of our DNA. Normally, LINE-1 doesn't cause much trouble, because it's blanketed by methyl groups (packets of one carbon atom bound to three hydrogen atoms).
In the current study, researchers led by Dana-Farber's Shuji Ogino, MD, PhD, MS, and Charles Fuchs, MD, MPH, found that for many colorectal cancer patients with a family history of the disease, the LINE-1 in their tumor cells was nearly bare of methyl groups (a condition known as hypomethylation).
"Previous studies have suggested that some colorectal cancers exhibit an instability of the epigenome, the cell's system for controlling when genes are active," says Ogino, the paper's first author. "One of the signs of this deficiency, it was proposed, is hypomethylation of LINE-1. We wanted to find whether a family history of colorectal cancer creates a higher risk of such hypomethylation."
Fuchs is the paper's senior author.
In contrast to a small, previous study, which suggested that LINE-1 hypomethylated colorectal cancers cluster in certain families, the new study took a large-scale "prospective" approach to gain more definitive insights. Investigators used data from the Nurses' Health Study and the Health Professionals Follow-up Study -- which follow the health of tens of thousands of people for decades -- to see if participants who had a family history of colorectal cancer tended to develop colorectal cancer with low-level methylation of LINE-1.
"We found that, compared to individuals without a family history of colorectal cancer, people who had first-degree relatives affected with the disease indeed had a higher risk of developing colorectal cancer with hypomethylated LINE-1," Ogino says. "Because this variety of colorectal cancer can quickly become dangerous, testing colorectal cancer patients for tumor LINE-1 hypomethylation may offer a valuable way of identifying those in greatest need of aggressive treatment. Such testing could also help identify patients whose relatives may be at increased risk for the aggressive form of the disease. Further study is needed to determine how this type of testing can be used in a clinical setting."
In addition to Ogino and Fuchs, the paper's co-authors are Reiko Nishihara, PhD, Paul Lochhead, MBChB, MRCP, Yu Imamura, MD, PhD, Aya Kuchiba, PhD, Teppei Morikawa, MD, PhD, Mai Yamauchi, PhD, Xiaoyun Liao, MD, PhD, Zhi Rong Qian, MD, PhD, Ruifang Sun, MB, Kaori Sato, MS, and Jeffrey Meyerhardt, MD, MPH, of Dana-Farber; Molin Wang, PhD, Donna Spiegelman, ScD, Eva S. Schernhammer, MD, DrPH, and Edward Giovannucci, MD, ScD, of the Harvard School of Public Health and BWH; Andrew T. Chan, MD, MPH, of BWH and Massachusetts General Hospital; and Gregory J. Kirkner, MPH, of BWH.
The study was funded in part by the National Institutes of Health (P01 CA87969, P01 CA55075, P50 CA127003, R01 CA151993, and R01 CA137178), the Bennett Family Fund for Targeted Therapies Research, and the National Colorectal Cancer Research Alliance.
Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It provides adult care with Brigham and Women's Hospital as Dana-Farber/Brigham and Women's Cancer Center, and it provides pediatric care with Boston Children's Hospital as Dana-Farber/Children's Hospital Cancer Center. Dana-Farber is the top-ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding. Follow Dana-Farber on Twitter: @dana-farber or Facebook: facebook.com/danafarbercancerinstitute.
Bill Schaller | EurekAlert!
Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications
Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State
Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.
Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
09.12.2016 | Life Sciences
09.12.2016 | Ecology, The Environment and Conservation
09.12.2016 | Health and Medicine